{"log_id": 1251691959398317976, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 0, "average": 0.99913, "min": 0.998638}, "location": {"width": 28, "top": 262, "height": 23, "left": 357}, "words": "75"}, {"probability": {"variance": 4.5e-05, "average": 0.992944, "min": 0.986256}, "location": {"width": 31, "top": 344, "height": 22, "left": 355}, "words": "60"}, {"probability": {"variance": 0.074321, "average": 0.727101, "min": 0.445775}, "location": {"width": 66, "top": 422, "height": 26, "left": 318}, "words": "况R45"}, {"probability": {"variance": 0.000838, "average": 0.977697, "min": 0.936753}, "location": {"width": 70, "top": 497, "height": 28, "left": 314}, "words": "袋30"}, {"probability": {"variance": 0.023827, "average": 0.932546, "min": 0.496978}, "location": {"width": 166, "top": 506, "height": 26, "left": 524}, "words": "0氯沙坦钾50mg"}, {"probability": {"variance": 0.02258, "average": 0.926749, "min": 0.590999}, "location": {"width": 76, "top": 537, "height": 24, "left": 563}, "words": "(n=33T"}, {"probability": {"variance": 3e-05, "average": 0.993869, "min": 0.988383}, "location": {"width": 30, "top": 582, "height": 23, "left": 356}, "words": "15"}, {"probability": {"variance": 0.000532, "average": 0.980898, "min": 0.921484}, "location": {"width": 168, "top": 582, "height": 26, "left": 557}, "words": "阿利沙坦酯240mg"}, {"probability": {"variance": 3.3e-05, "average": 0.995306, "min": 0.982135}, "location": {"width": 75, "top": 614, "height": 22, "left": 561}, "words": "(n=344)"}, {"probability": {"variance": 0, "average": 0.882044, "min": 0.882044}, "location": {"width": 18, "top": 663, "height": 20, "left": 367}, "words": "0"}, {"probability": {"variance": 1.1e-05, "average": 0.998078, "min": 0.989445}, "location": {"width": 366, "top": 687, "height": 30, "left": 378}, "words": "基线4周8周12周"}, {"probability": {"variance": 0.001906, "average": 0.990767, "min": 0.755861}, "location": {"width": 786, "top": 793, "height": 35, "left": 249}, "words": "图1.阿利沙坦酯与氯沙坦钾在临床对照试验中的结果比较。有效指"}, {"probability": {"variance": 0.001956, "average": 0.983427, "min": 0.74332}, "location": {"width": 783, "top": 841, "height": 30, "left": 251}, "words": " SBP/DBP<140mmHg/85mmHg或SBP下降20mmHg和或DBP下降10mmHg。达标"}, {"probability": {"variance": 0, "average": 0.95016, "min": 0.95016}, "location": {"width": 20, "top": 869, "height": 34, "left": 1188}, "words": "6"}, {"probability": {"variance": 0.009547, "average": 0.85715, "min": 0.628548}, "location": {"width": 317, "top": 892, "height": 23, "left": 253}, "words": " DESBP/DBP<140mmhg/90mmhg"}, {"probability": {"variance": 0, "average": 0.966801, "min": 0.966801}, "location": {"width": 28, "top": 925, "height": 27, "left": 1015}, "words": "U"}, {"probability": {"variance": 0, "average": 0.981277, "min": 0.981277}, "location": {"width": 18, "top": 927, "height": 24, "left": 1177}, "words": "3"}, {"probability": {"variance": 1e-06, "average": 0.99913, "min": 0.9975}, "location": {"width": 130, "top": 961, "height": 28, "left": 241}, "words": "【药理毒理】"}, {"probability": {"variance": 4e-06, "average": 0.998288, "min": 0.994834}, "location": {"width": 94, "top": 1008, "height": 27, "left": 235}, "words": "作用机制"}, {"probability": {"variance": 0.00264, "average": 0.985397, "min": 0.703561}, "location": {"width": 765, "top": 1049, "height": 33, "left": 279}, "words": "血管紧张素ⅡI(AngⅡ)是由血管紧张素I(AngI)经过血管紧张素转化"}, {"probability": {"variance": 5.5e-05, "average": 0.996321, "min": 0.963257}, "location": {"width": 806, "top": 1097, "height": 30, "left": 237}, "words": "酶(ACE,激肽酶Ⅱ)催化转化而成的,是肾素一血管紧张素系统(RAS)的"}, {"probability": {"variance": 0.002982, "average": 0.985014, "min": 0.69268}, "location": {"width": 811, "top": 1142, "height": 34, "left": 234}, "words": "关键性产物,在高血压的病理生理过程中起主要作用。AngⅡ受体有两种:1型"}, {"probability": {"variance": 3.3e-05, "average": 0.997614, "min": 0.970553}, "location": {"width": 798, "top": 1191, "height": 30, "left": 245}, "words": "(AT1)和2型(AT2)。在很多组织(如血管平滑肌、肾上腺、肾脏和心脏)中"}, {"probability": {"variance": 0.00297, "average": 0.988982, "min": 0.676172}, "location": {"width": 808, "top": 1239, "height": 31, "left": 236}, "words": " Ang II和AT1受体结合,引起几种重要的生物学作用,包括血管收缩、醛固酮"}, {"probability": {"variance": 8.4e-05, "average": 0.996562, "min": 0.945807}, "location": {"width": 807, "top": 1284, "height": 32, "left": 234}, "words": "释放、心脏收缩、钠重吸收和刺激平滑肌细胞增生等。AT2受体分布也较广"}, {"probability": {"variance": 3e-06, "average": 0.998838, "min": 0.992859}, "location": {"width": 541, "top": 1329, "height": 32, "left": 235}, "words": "泛,但它对于心血管系统功能稳态的作用尚不明确"}, {"probability": {"variance": 2e-05, "average": 0.99772, "min": 0.97431}, "location": {"width": 762, "top": 1378, "height": 30, "left": 280}, "words": "阿利沙坦酯经酯酶代谢产生与氯沙坦钾经肝脏代谢产生相同的活性代谢产"}, {"probability": {"variance": 0.0007, "average": 0.989985, "min": 0.832444}, "location": {"width": 808, "top": 1425, "height": 31, "left": 236}, "words": "物E3174(单次口服阿利沙坦酯240mg或氯沙坦钾100mg,生成的E3174的"}, {"probability": {"variance": 0.00216, "average": 0.975797, "min": 0.737607}, "location": {"width": 809, "top": 1472, "height": 31, "left": 236}, "words": " Auclast分别为4.3hr*mg/L和4.76hr*mg/L)。E3174能与AT1受体选择性结"}, {"probability": {"variance": 1.6e-05, "average": 0.998161, "min": 0.978695}, "location": {"width": 793, "top": 1520, "height": 30, "left": 237}, "words": "合,阻断任何来源或任何途径合成的血管紧张素Ⅱ所产生的相应的生理作用"}, {"probability": {"variance": 0.000182, "average": 0.97931, "min": 0.967553}, "location": {"width": 34, "top": 1581, "height": 20, "left": 638}, "words": "/11"}], "language": 3}